The following is a collection of information and news about Trikafta®, the triple-combination modulator therapy.

2 min read

Trikafta® is a highly effective therapy for the underlying cause of cystic fibrosis. It is approved for use in people with CF ages 6 and older who have at least one copy of the F508del mutation or certain mutations in the CFTR gene that are responsive based on lab data.

This page will be updated with new information as it becomes available.

Share this article
CFTR Modulators
Have questions? We’re here to help. Call us at 1-800-FIGHT CF

Mon - Thu, 9 am - 7 pm ET
Fri, 9 am - 3 pm ET


More Ways To Get Help